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Nadine Dohollou, MD,†† Miche`le Besenval, MD,‡‡ and Elisabeth Quoix, MD§§
Introduction: This randomized phase II study investigated the
efficacy and safety of a new taxane, larotaxel (XRP9881), in com-
bination with either cisplatin or gemcitabine in the first-line treat-
ment of patients with nonirradiable stage IIIB or stage IV non-small
cell lung cancer to select the combination having the most promising
antitumor activity.
Methods: Patients received either larotaxel (50 mg/m2) as a 1-hour
infusion, followed by a 1-hour infusion of cisplatin (75 mg/m2),
every 3 weeks (arm A), or gemcitabine (800 mg/m2) as a 30 minute
infusion, on days 1 and 8, and larotaxel (60 mg/m2) as a 1-hour
infusion, on day 8 (following gemcitabine), every 3 weeks (arm B).
The primary end point was the objective response rate (per-protocol
population).
Results: Thirty-two patients were randomized to arm A and 30 to
arm B. The response rate was higher in arm A compared with arm
B in both the per-protocol (26.7% versus 18.2%) and intention-to-
treat (28.1% versus 13.3%) populations. In the intention-to-treat
population, median progression-free survival for arm A versus arm
B was 4.7 versus 3.3 months and median overall survival was 8.6
versus 7.3 months, respectively. Fifty percent of patients in arm A
and 66.7% in arm B experienced at least one National Cancer
Institute common toxicity criteria grade 3/4 adverse event and grade
3/4 neutropenia was observed in 46.9% and 41.4% of patients,
respectively.
Conclusions: Both larotaxel combinations were effective and man-
ageable, however all measured efficacy parameters (response rate,
progression free survival, and survival) seemed to favor the combi-
nation with cisplatin.
Key Words: Advanced NSCLC, Combination chemotherapy, First-
line, Taxane, Larotaxel.
(J Thorac Oncol. 2008;3: 894–901)
Globally, lung cancer is the most frequently diagnosedmalignancy and the disease remains the most common
cause of cancer-related death.1 The majority of tumors
(80%) are non-small cell lung cancers (NSCLCs).2 As a
consequence of the absence of effective, clinically-validated
screening procedures, most NSCLCs are locally advanced or
metastatic at presentation (stage IIIB and IV),3 and therefore
nonresectable. Treatment for advanced disease may comprise
chemoradiotherapy (stage IIIB) or chemotherapy (stage IV).4
Such essentially palliative treatment aims at controlling symp-
toms, improving quality of life, and lengthening survival.
A number of cytotoxic agents have been shown to be
effective as first-line treatments for NSCLC. Currently, pa-
tients with good performance status will commonly receive a
doublet comprising a platinum analogue (cisplatin or carbo-
platin) combined with a third-generation cytotoxic agent
(gemcitabine, vinorelbine, or a taxane). Various combina-
tions seem to be essentially equally effective,5,6 with differ-
ences between regimens primarily limited to their side
effect profiles.7,8 Nonplatinum-based doublets, especially
gemcitabine plus a taxane have been developed in an
attempt to overcome cisplatin-associated toxicities. Re-
sults available at time of this study led to the recommen-
dation by American Society of Clinical Oncology in 2003
of their use as an alternative to platinum-based doublets.4
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The taxanes, paclitaxel and docetaxel, are both effec-
tive and approved in combination with platinum in first-line
NSCLC therapy.9 Docetaxel is also approved as a single
agent for second-line treatment. There is however a need to
increase the effectiveness of such compounds in relation to
increasing cytotoxicity in taxane-resistant tumors and de-
creasing systemic toxicity.10 Larotaxel (XRP9881) is a novel
semi-synthetic taxane compound that seems to be a potent
microtubule stabilizer, blocking tubulin disassembly and
thereby inhibiting mitosis. The drug efflux pump, P-glyco-
protein 1 (encoded by the multidrug resistance gene, ABCB1),
which is commonly overexpressed in tumors, may play a key
role in taxane resistance. Larotaxel has a much lower affinity
for P-glycoprotein 1 than docetaxel and was shown to be
active in cell lines resistant to doxorubicin, vinblastine, pac-
litaxel, and docetaxel. In addition, this compound seems to
cross the blood-brain barrier.11
Several phase I studies have explored different sched-
ules of administration of larotaxel as a single agent and have
recommended dose levels for phase II studies of 60 and 90
mg/m2 for the every 3 weeks regimen.11–15 Hematologic
toxicity was the main dose-limiting toxicity in all the tested
regimens. Other nonhematologic toxicities characteristically
associated with taxanes, such as alopecia, gastrointestinal
effects, neurosensory disorders, hypersensitivity reactions,
skin disorders, and fluid retention were generally mild or
moderate. Objective responses were observed in several tu-
mor types. Of particular interest, Sessa and colleagues noted
responses in three NSCLC patients. In one case, a response
was seen in both the patient’s primary tumor and also asso-
ciated brain metastases.11 This study provided a rational basis
for the further testing of larotaxel in advanced NSCLC
patients.
A preliminary three-arm phase I study investigated
larotaxel in combination with cisplatin, gemcitabine, or vi-
norelbine. The recommended doses for the combination of
larotaxel and cisplatin were 50 and 75 mg/m2, respectively
and for larotaxel and gemcitabine; 60 and 800 mg/m2, re-
spectively. However, larotaxel combined with vinorelbine
showed poor tolerability, even at the lowest doses tested, and
so this combination was rejected for phase II development
(manuscript in preparation). Using response rate as the pri-
mary efficacy measure, the current phase II study was de-
signed to investigate whether cisplatin or gemcitabine was the
most appropriate partner for larotaxel in patients with che-
motherapy naive advanced NSCLC.
PATIENTS AND METHODS
Major Eligibility Criteria
Chemotherapy naive patients were eligible for inclu-
sion if they had histologically or cytologically-confirmed
nonirradiable stage IIIB or stage IV NSCLC and were 18
and 75 years of age, with a life expectancy of at least 12
weeks and an Eastern Cooperative Oncology Group perfor-
mance status of 0 to 2. They were not to have received
surgery for NSCLC within the previous 4 weeks (excluding
simple surgery for diagnosis or to implant a venous access
device) and required adequate hematologic (neutrophils
2 109/l, platelet count 100 109/l), renal (creatinine
within upper normal limits or if borderline, with a creatinine
clearance 60 mL/min), and hepatic (total bilirubin within
normal limits, serum aspartate aminotransferase/alanine ami-
notransferase and alkaline phosphatase 2.5 times the upper
limits of normal or aspartate aminotransferase/alanine ami-
notransferase 1.5 times associated with alkaline phospha-
tase 5 times the upper limits of normal) function. Patients
were required to have at least one measurable lesion accord-
ing to response evaluation criteria in solid tumors criteria.16
The study was conducted in accordance with the declaration
of Helsinki and written informed patient consent was ob-
tained before the implementation of any study-related proce-
dures.
Main exclusion criteria were: a prior history of cancer
(excluding basal cell skin or in situ disease); symptomatic
brain or leptomeningeal metastases; hypercalcemia (2.8
mmol/l); peripheral neuropathy  grade 1; another serious
comorbid condition; had received prior chemotherapy or
radiotherapy (except for bone metastases) or were receiving
another anticancer treatment or experimental drug.
Study Design and Treatments
This was a multicenter, randomized study conducted in
11 centers in four countries (France, Belgium, Czech Repub-
lic and Switzerland). The primary objective was to select the
combination having the most promising antitumor activity
(response rate). Patients were randomly assigned centrally
into two arms. Those in arm A received larotaxel (50 mg/m2)
as a 1-hour infusion, followed after 30 minutes by a 1-hour
infusion of cisplatin (75 mg/m2), every 3 weeks. Patients in
arm B received gemcitabine (800 mg/m2) as a 30 minute
infusion, on days 1 and 8, and larotaxel (60 mg/m2) as a
1-hour infusion, on day 8 (following gemcitabine, with no
interval), every 3 weeks. Administration of larotaxel on day
8 in this arm was selected to match docetaxel/gemcitabine
NSCLC schedules, which have been designed to avoid do-
cetaxel-induced neutropenia (which generally occurs 5 to 8
days after administration) causing a delay in the day 8
administration of gemcitabine.17 All patients in arm A re-
ceived a setron (ondansetron or alternative) as a prophylactic
antiemetic premedication from cycle 1. Patients in this arm
were to be adequately hydrated to avoid the nephrotoxicity
secondary to cisplatin administration. No prophylactic anti-
emetic drugs were allowed during the first cycle for patients
in arm B. In subsequent cycles, in the case of nausea/
vomiting, patients could receive preventive antiemetic treat-
ment in compliance with the standard protocol of the center.
Prophylaxis with dexamethasone was given (16 mg the day
before, 24 mg the day of, and 16 mg the day after larotaxel
administration).
Adverse events (AEs) were graded according to Na-
tional Cancer Institute-Common Toxicity Criteria Version 2.
In the event of long lasting AEs, the cycle could be extended
for 1 week. No dose reduction was permitted for arm A and
if such toxicity did not resolve by day 28, the patient was to
discontinue the study treatment. For arm B, in the case of
severe toxicity related to larotaxel or gemcitabine, a dose
reduction to 50 and/or 650 mg/m2, respectively, was allowed.
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The interval between day 1 of 2 consecutive cycles could be
extended to 5 weeks for nondrug-related AEs, but only once
during the study. Treatment was continued until disease
progression, unacceptable toxicity, or the withdrawal of pa-
tient consent.
Evaluations Before and During Therapy
Within 7 days before first study drug administration,
medical history (including NSCLC histology/cytology, prior
surgery other than for cancer, concurrent illness, prior med-
ications, history of allergy) was recorded and a physical
examination (height, weight, Eastern Cooperative Oncology
Group performance status, vital signs) carried out. Standard
hematologic and biochemical analyses and an evaluation of
existing signs and symptoms were also completed. Within 4
weeks before treatment a cardiologic examination and radio-
logic scanning of the chest (x-ray or computed tomography;
CT), abdomen (CT), brain (CT or magnetic resonance imag-
ing) and when indicated, bone (scan or x-ray) were carried
out, encompassing all target and nontarget (when indicated)
lesions. During the study, a physical examination was carried
out immediately before treatment, on day 1 of each cycle.
Toxicity was evaluated weekly. Hematologic assessments
were carried out every week, or every other day in the case of
grade four neutropenia or thrombopenia (arm B) until recov-
ery to grade 3 or 3, respectively. Radiologic assessment
of the chest and abdomen and all target and nontarget lesions
was performed every 2 cycles (6 weeks) using the same
method as the baseline evaluation.
Statistical Methods and Considerations
The intention-to-treat (ITT) population comprised all
randomized patients. The per-protocol population (PPP) was
defined as a subset of the treated population: patients had to
be eligible, evaluable for response, and without any major
protocol deviations during the course of the study. The safety
population was the treated population, defined as all patients
who had been administered at least one (even incomplete)
infusion of one study drug.
The primary objective was to rank the activity of the
two test regimens using the Simon design.18 An independent
External Response Review Committee reviewed radiologic
assessments to evaluate the best tumor response and to
establish the date of progression (response evaluation criteria
in solid tumors16). The primary efficacy variable was the
objective response rate for the PPP, as assessed by the
External Response Review Committee and as defined by
the percentage of patients achieving a confirmed complete
(CR) or partial (PR) response (CR  PR). Twenty-one pa-
tients/arm were to be included. Taking into account a likely
rate of exclusion from the PPP of 10%, 23 patients/arm were
to be enrolled. With this sample size, and assuming that the
lowest response rate was 10%, there was a probability of 90%
that the best treatment would be selected, provided that it was
superior to the other by at least 15%.
Secondary efficacy variables included: duration of re-
sponse (DR; defined as the time interval between meeting the
criteria for a CR or PR and the date of the first documented
progression or death from any cause), duration of stable
disease (SD) (defined as the time from randomization until
disease progression or death for patients with SD as best
overall response), progression-free survival (PFS; defined as
the time from randomization until disease progression or
death), and overall survival (OS; defined as the time from
randomization until death). For DR and PFS evaluations,
progression or death occurring 84 days or more after the last
evaluable tumor assessment was censored back to the date of
that assessment. OS was censored at the date of last contact
or the cutoff date, whichever came first.
Categoric variables were summarized by frequency and
percentage. Ninety five percent confidence intervals [95%]
were calculated using the Clopper–Pearson exact method,19
where appropriate. Continuous variables were presented with
summary statistics (mean, standard deviation, median, range).
Kaplan–Meier curves20 and estimates21 (median and its 95%
confidence interval) were used to analyze variables of dura-
tion and event.
RESULTS
Patient Demographics
Sixty-two patients were randomized between 30th July
2002 and 17th June 2003: 32 to arm A (larotaxel/cisplatin)
and 30 to arm B (larotaxel/gemcitabine). Patient characteris-
tics at baseline were generally well balanced between the
arms, except gender (Table 1). Similarly, baseline tumor
characteristics were well balanced with only slight differ-
ences in the interarm frequencies of the number and type of
organs involved and stage of disease at first diagnosis (Table
1). The majority of patients had stage IV disease, with
adenocarcinoma being the most common histologic class.
Most patients had three or more organs affected.
Treatment Administration
Thirty-two patients in arm A received a total of 127
cycles (median 4, range 1–8) and 30 patients in arm B
received a total 116 cycles (median 4, range 1–6). Table 2
summarizes drug exposure. Reflecting the absence of proto-
col-permitted dose reduction in arm A, the relative dose
intensity was 0.98 for both larotaxel and cisplatin. In arm B,
28 of 30 patients received larotaxel, with 2 discontinuing
treatment immediately after the first gemcitabine infusion
(day 1) following, in 1 case, grade 4 supraventricular arrhyth-
mia and in 1 case, pulmonary embolism (neither considered
related to study treatment). The relative dose intensity in this
arm for larotaxel was 0.94 and for gemcitabine was 0.93, with
these intensities demonstrating the feasibility of the combi-
nation. Although not allowed, 1 (3.1%) patient (1 cycle,
0.8%) in arm A did have a dose reduction (larotaxel; cycle 3)
following anemia. In arm B, 7 (23.3%) patients experienced
a dose reduction in 9 cycles (7.8%), due to hematologic
toxicity for two patients, nonhematologic toxicity for three
patients (diarrhea, nausea, and vomiting); for the two remain-
ing patients no specific reason was given. Among the 9 cycles
with dose reduction, larotaxel was reduced in eight and
gemcitabine in one. Eleven patients (34.4%) in arm A and 13
patients (43.3%) in arm B had a delay in at least 1 cycle. A
total of 16 (12.6%) cycles were delayed in arm A and 22
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(19.0%) in arm B. The most common reasons for cycle delays
were other reason (administrative reasons) in arm A and
hematologic toxicity in arm B. All patients had discontinued
treatment by the cutoff date of 15th May 2005, with the most
common reason in both arms being progressive disease,
followed by no further benefit expected and adverse event.
Efficacy
Primary and secondary efficacy data are detailed in
Table 3. There were no CR. Response rates in the PPP for
arm A and arm B were 26.7% and 18.2% and for the ITT
population 28.1% and 13.3%, respectively. In addition,
40.0% and 36.4% (PPP), 40.6% and 33.3% (ITT) of patients
respectively had SD. In brain lesions (10 patients), no objec-
tive responses were observed but stabilization was achieved
in three of four patients in arm A and one of six in arm B.
As only 13 patients (including six censored in arm A
and two in arm B) had an objective response, Kaplan–Meier
plots for DR were not constructed. The DR ranged between
1.45 and 20.63 months. Median PFS was similar in arm
A of the PPP compared with arm B (4.3 versus 4.4 months)
but a difference of 1.4 months was observed in the ITT
population (4.7 versus 3.3 months, respectively). In arm B,
two out of four patients with very short PFS were excluded
from the PPP (baseline tumor assessment done more than 31
days before first infusion) and probably explain the difference
in PFS between ITT and PPP. In the ITT population, median
OS was 8.6 months in arm A and 7.3 months in arm B (Figure
1) and the 1-year survival rate was 40.6% in arm A and
30.0% in arm B.
Safety
Eight (25.0%) patients in arm A and nine (30.0%)
patients in arm B experienced grade 3/4 treatment emergent
adverse events related to study treatment (Table 4). The
highest incidences of such events (nonhematological) were
infection (9.4%) and vomiting (6.3%) in arm A, and infection
(10.0%), diarrhea and allergic reaction (6.7%) in arm B. Of
note, a similar rate of patients experienced grade 3/4 infection
related to study treatment. However, more patients experi-
enced grade 3/4 infection regardless of relationship to study
treatment (with or without neutropenia) in arm B compared
with arm A (12.5% in arm A; 26.7% in arm B). Given that the
excess of infection cases in arm B seemed not to be related to
treatment, that the patients were randomized to the study
arms and that there were no obvious imbalances in patient/
disease characteristics at baseline that might explain this
excess, this is most likely a chance finding.
Neutropenia was the most common grade 3/4 hemato-
logic toxicity in both arms (arm A: 46.9%, arm B: 41.4%),
with grade 3/4 thrombocytopenia reported for only one pa-
tient (3.4%) in arm B. Two (6.3%) patients experienced
febrile neutropenia in arm A (no patients in arm B), and three
(10.0%) patients experienced neutropenic infection in each
arm.
The incidence of peripheral neurotoxicity was similar
in both arms (arm A: 18.8%, arm B: 20.0%) with no patients
experiencing grade 3. More any grade creatinine increase was
noted for arm A compared with arm B (37.5% versus 10%).
However, this was grade 1 in all but two (6.3%) patients
(grade 2, which subsequently improved to grade 1).
One patient in arm A (3.1%) and four patients in arm B
(13.3%) died within 30 days of the last treatment adminis-
tration (Table 5). Two of the deaths in arm B (6.7%) were
considered to be related to study treatment: one patient died
of infection (with concomitant grade 3/4 neutropenia) on day
11 of the last infusion at cycle 2, and another died of infection
(with concomitant grade 3/4 neutropenia) on day 7 of the last
infusion at cycle 1.
TABLE 1. Patient and Disease Characteristics at Baseline
Characteristic
Arm A
(N  32)
Arm B
(N  30)
All Patients
(N  62)
Gender, n (%)
Male 21 (65.6) 26 (86.7) 47 (75.8)
Female 11 (34.4) 4 (13.3) 15 (24.2)
Race, n (%)
Caucasian 32 (100.0) 30 (100.0) 62 (100.0)
Age, yr
Median (range) 57 (43–75) 62 (40–72) 60 (40–75)
65 yr, n (%) 21 (65.6) 22 (73.3) 43 (69.4)
65 yr, n (%) 11 (34.4) 8 (26.7) 19 (30.6)
PS before first infusion, n (%)
Median (range) 1 (0–2) 1 (0–2) 1 (0–2)
0 9 (28.1) 7 (23.3) 16 (25.8)
1 20 (62.5) 19 (63.3) 39 (62.9)
2 3 (9.4) 4 (13.3) 7 (11.3)
Signs and symptoms at
baseline, n (%)
27 (84.4) 28 (93.3) 55 (88.7)
Histology type, n (%)
Adenocarcinoma 17 (53.1) 15 (50.0) 32 (51.6)
Large cell carcinoma 2 (6.3) 4 (13.3) 6 (9.7)
NSCLC undetermined 2 (6.3) — 2 (3.2)
Squamous cell carcinoma 11 (34.4) 11 (36.7) 22 (35.5)
Stage of disease at baseline
IIIB 5 (15.6) 5 (16.7) 10 (16.1)
IV 27 (84.4) 25 (83.3) 52 (83.9)
Measurable disease, n (%) 32 (100.0) 30 (100.0) 62 (100.0)
Number of organs involved
1 1 (3.1) 4 (13.3) 5 (8.1)
2 12 (37.5) 6 (20.0) 18 (29.0)
3 13 (40.6) 15 (50.0) 28 (45.2)
4 or more 6 (18.8) 5 (16.7) 11 (17.7)
Organ involvement, n (%)
Lung 30 (93.8) 24 (80.0) 54 (87.1)
Soft tissue (lymph nodes) 27 (84.4) 22 (73.3) 49 (79.0)
Brain 4 (12.5) 6 (20.0) 10 (16.1)
Bone 9 (28.1) 5 (16.7) 14 (22.6)
Adrenal gland 6 (18.8) 8 (26.7) 14 (22.6)
Liver 5 (15.6) 7 (23.3) 12 (19.4)
Pleura 5 (15.6) 6 (20.0) 11 (17.7)
Arm A, larotaxel  cisplatin; Arm B, larotaxel  gemcitabine; PS, performance
status; NSCLC, non-small cell lung cancer.
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FIGURE 1. Kaplan–Meier curve for overall sur-
vival in the ITT population.
TABLE 2. Exposure to Treatment
Exposure
Arm A Arm B
Larotaxel Cisplatin Larotaxel Gemcitabine
No. of treated patients 32 32 28 30
Cumulative dose, (mg/m2)
Median (range) 200.9 (49.3–397.9) 301.4 (73.9–588.4) 238.0 (59.5–364.9) 6373.3 (767.1–9731.8)
Actual dose intensity, (mg/m2/wk)
Median (range) 16.3 (14.3–17.4) 24.5 (21.3–25.7) 18.9 (10.9–20.2) 498.3 (255.7–539.9)
Relative dose intensity
Median (range) 0.98 (0.86–1.04) 0.98 (0.85–1.03) 0.94 (0.54–1.01) 0.93 (0.48–1.01)
TABLE 3. Primary and Secondary Efficacy Data in the Per-Protocol and ITT Populations
Parameter
PPP ITT
Arm A (N  30) Arm B (N  22) Arm A (N  32) Arm B (N  30)
Response, n (%)
Complete response (CR) — — — —
Partial response (PR) 8 (26.7) 4 (18.2) 9 (28.1) 4 (13.3)
No change/stable disease 12 (40.0) 8 (36.4) 13 (40.6) 10 (33.3)
Progressive disease 8 (26.7) 9 (40.9) 8 (25.0) 10 (33.3)
Not evaluable 2 (6.7) 1 (4.5) 2 (6.3) 6 (20)
Overall response rate (CR  PR) 8a (26.7) 4 (18.2) 9 (28.1) 4 (13.3)
95% CI 12.3, 45.9 5.2, 40.3 13.7, 46.7 3.8, 30.7
Median PFS (mo) 4.3 4.4 4.7 3.3
95% CI 2.76, 4.96 1.54, 6.08 2.92, 6.21 1.45, 5.42
Median overall survival (mo) ND ND 8.6 7.3
95% CI 5.39, 16.03 4.76, 11.07
1-yr survival (mo) 40.6% 30.0%
a One patient achieving a response was ineligible for inclusion in the PPP population as a consequence of major protocol deviations at study
entry (baseline tumor assessment more than 31 d prior to first infusion and previous radiotherapy).
PPP, per-protocol population; ITT, intention to treat population; Arm A, larotaxel  cisplatin; Arm B, larotaxel  gemcitabine; PFS,
progression-free survival; ND, not determined; CI, confidence interval.
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DISCUSSION
Cisplatin is one of the most efficient drugs in NSCLC,
but requires hyperhydration and induces some cumulative
toxicities that may be difficult to manage such as renal
impairment, peripheral neuropathy, and ototoxicity. To de-
crease toxicity associated with cisplatin-based doublets, a
number of studies have investigated whether carboplatin-
based and nonplatinum combinations including gemcitabine
instead of cisplatin might confer equivalent efficacy but lower
toxicity. A first meta-analysis has suggested the superiority of
TABLE 4. Summary of Adverse Events in Each Study Arm, Treatment Emergent Adverse Events Related to Study Treatment
by Category and Terms (Reported for 2 Patients at Grade 3/4 or 3 Patients at any Grade) and Hematological Toxicity
Adverse Events Summary, N (%)
Arm A
(N  32)
Arm B
(N  30)
At least one TEAE regardless of
relationship to study treatment
30 (93.8) 30 (100.0)
At least one TEAE possibly or
probably related to study treatment
26 (81.3) 26 (86.7)
At least one grade 3/4 TEAE
regardless of relationship to
study treatment
16 (50.0) 20 (66.7)
At least one grade 3/4 TEAE
possibly or probably related to
study treatment
8 (25.0) 9 (30.0)
Adverse Events: NCI-CTC
Category/Term, N (%) Grade 3/4 Any Grade Grade 3/4 Any Grade
Allergy/immunology — 4 (12.5) 2 (6.7) 3 (10.0)
Allergic reaction/hypersensitivity — 4 (12.5) 2 (6.7) 3 (10.0)
Cardiovascular (general) — 2 (6.3) — 5 (16.7)
Edema — 1 (3.1) — 3 (10.0)
Constitutional symptoms 2 (6.3) 14 (43.8) — 11 (36.7)
Fatigue 1 (3.1) 13 (40.6) — 9 (30.0)
Fever — 3 (9.4) — 3 (10.0)
Dermatology — 14 (43.8) — 19 (63.3)
Alopecia — 14 (43.8) — 16 (53.3)
Rash/desquamation — 1 (3.1) — 5 (16.7)
Gastrointestinal 3 (9.4) 22 (68.8) 3 (10.0) 19 (63.3)
Anorexia — 8 (25.0) — 7 (23.3)
Constipation — 4 (12.5) — 2 (6.7)
Diarrhea 1 (3.1) 10 (31.3) 2 (6.7) 10 (33.3)
Nausea — 17 (53.1) 1 (3.3) 15 (50.0)
Stomatitis/pharyngitis — 3 (9.4) — 4 (13.3)
Vomiting 2 (6.3) 12 (37.5) 1 (3.3) 10 (33.3)
Infection 3 (9.4) 3 (9.4) 3 (10.0) 4 (13.3)
Infectiona 3 (9.4) 3 (9.4) 3 (10.0) 3 (10.0)
Neurology — 7 (21.9) — 7 (23.3)
Neuropathy sensory — 6 (18.8) — 6 (20.0)
Pain — 4 (12.5) 1 (3.3) 5 (16.7)
Abdominal pain cramping — 3 (9.4) — 1 (3.3)
Hematological
Leukopenia 9 (28.1) 19 (59.4) 8 (27.6) 18 (62.1)
Neutropenia 15 (46.9) 21 (65.6) 12 (41.4) 19 (65.5)
Anemia 3 (9.4) 29 (90.6) 1 (3.4) 26 (89.7)
Thrombocytopenia — — 1 (3.4) 11 (37.9)
Neutropenic complications
Febrile neutropenia 2 (6.3) —
Related neutropenic infection
Grade 3
2 (6.3) 1 (3.3)
Related neutropenic infection
Grade 4
1 (3.1) 2 (6.7)
a Neutropenic infection.
Arm A, larotaxel  cisplatin; Arm B, larotaxel  gemcitabine; NCI-CTC, National Cancer Institute Common Toxicity Criteria; TEAE, treatment emergent adverse event.
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cisplatin over carboplatin in terms of survival.22 Another
recent meta-analysis of 11 phase III studies has indicated that
patients treated with a platinum-based regimen benefited
from a statistically significant reduction in the risk of death at
1 year (p  0.04) compared with those receiving a nonplati-
num regimen. This benefit was associated with a significantly
increased but acceptable risk of severe toxicity.23 Following
these two meta-analyses, the standard of care in this setting
therefore remains a cisplatin-based doublet.
The objective of the current study was to investigate the
activity and tolerability of a new taxane, larotaxel, combined
with either cisplatin (arm A) or gemcitabine (arm B) in the
first-line treatment of NSCLC. The objective response rates
favored arm A over arm B in both the per-protocol (differ-
ence of 8.5%) and ITT (difference of 14.8%) populations. In
addition, with the caution due to the small sample size in both
arms, the observed median OS time was longer in the ITT
population for larotaxel combined to cisplatin compared with
larotaxel combined to gemcitabine by 8.6 and 7.3 months and
the 1-year survival rate was higher (40.6% versus 30.0%,
respectively).
Several phase II and large phase III studies have re-
ported efficacy data for docetaxel/cisplatin or paclitaxel/
cisplatin combinations used as first-line treatments for ad-
vanced NSCLC. Response rates ranged between 17% and
37%, with median OS lying between 7.4 and 11.3 months and
1-year survival between 31% and 48%.6,24–26 Efficacy param-
eters for larotaxel/cisplatin are therefore included within
these ranges. However, efficacy parameters for larotaxel/
gemcitabine generally compare less favorably with the
taxane/gemcitabine arms of phase II and III first-line NSCLC
studies, in which response rates were reported to lie between
20% and 35%, OS between 6.8 and 13 months and 1-year
survival between 30% and 56%.27–31 Efficacy data in the
current study therefore favor the combination of larotaxel/
cisplatin, especially given the meta-analysis data indicating
that platinum-based doublets may generally be more effective
than nonplatinum regimens.23
The overall incidence of grade 3/4 toxicities related to
study treatment was comparable between arms. However,
grade 3/4 infection, with or without neutropenia was more
common in arm B including two treatment-related deaths,
due to neutropenic infection. Levels of neurotoxicity were
comparable between arms and with no grade 3/4 events
observed. Severe neurotoxicity seemed to be less common
than has previously been reported for taxane/cisplatin com-
binations.6,24,26 Renal toxicity, which was more frequent in
arm A, was mild (grade 1 or 2) as was edema, which occurred
in 3% and 10% of patients in arms A and B, respectively. Nail
changes, characteristically associated with taxane therapy,32
were not reported for any patient. The safety profile of both
combinations was considered to be acceptable.
In summary, although there were some differences in
the safety profile, with more grade 1/2 renal toxicity with
larotaxel/cisplatin, and more infection with larotaxel/gemcit-
abine, this study has demonstrated that larotaxel in combina-
tion with either cisplatin or gemcitabine is feasible. As for
previous new agents in NCSLC, and noting that the results of
this randomized phase II study cannot be generalized to other
untested nonplatinum/larotaxel combinations, the combina-
tion of larotaxel with cisplatin had a more favorable efficacy
(comparable to established taxane/cisplatin combinations)
than the combination of larotaxel with a nonplatinum com-
pound. Future phase II studies exploring the efficacy of
cisplatin/larotaxel/targeted agent combinations in this setting
can be envisaged.
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